The FDA has approved SIR-Spheres Y-90 resin microspheres for treating patients with unresectable hepatocellular carcinoma (HCC) who meet specific clinical criteria, such as no macrovascular invasion, Child-Pugh A cirrhosis, and well-compensated liver function. The approval is supported by the DOORwaY90 study, a multicenter trial evaluating Y-90 as a first-line therapy for unresectable HCC. Results were remarkable, showing a 98.5% overall response rate and 100% local tumor control, with a median duration of response exceeding 300 days. The treatment also showed an excellent safety profile.
A key factor in the study’s success was the use of centralized, standardized partition dosimetry and detailed treatment verification through collaborative virtual planning and imaging review. This rigorous method ensured accuracy and consistency across all sites, leading to exceptional outcomes.
Historically, chemoembolization was the standard option for HCC, but data now indicate that radioembolization (Y-90) is becoming the preferred therapy, especially for early-stage or transplant-eligible patients. Experts believe these findings will accelerate the transition toward Y-90 as a frontline treatment. Principal investigator Dr. Armeen Mahvash emphasized that centralized planning and verification are not only feasible but set a new benchmark for Y-90 studies. The next challenge is helping physicians adopt these advanced methods in clinical practice to improve patient outcomes.